文献速递产科母胎医学

血清淀粉样蛋白A1与妊娠区带蛋白在妊娠并发症中的水平及其与胎盘功能障碍标志物的相关性

Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-11-09

本研究检测了549例妊娠孕妇血浆中血清淀粉样蛋白A1与妊娠区带蛋白水平,比较正常对照与早发型子痫前期、晚发型子痫前期、妊娠期高血压、慢性高血压及糖尿病组的差异。早发型子痫前期血清淀粉样蛋白A1较对照升高(17.1 vs 5.1 µg/mL,P<.001),妊娠区带蛋白降低(590 vs 892 µg/mL,P=.002);糖尿病组妊娠区带蛋白亦低于对照(683 vs 892 µg/mL,P=.01)。血清淀粉样蛋白A1与胎盘功能障碍相关,妊娠区带蛋白与可溶性fms样酪氨酸激酶-1/胎盘生长因子比值呈负相关。

要点

  • 早发型子痫前期血清淀粉样蛋白A1较正常对照升高(17.1 vs 5.1 µg/mL,P<.001)。
  • 早发型子痫前期妊娠区带蛋白较对照降低(590 vs 892 µg/mL,P=.002),糖尿病组亦降低(683 vs 892 µg/mL,P=.01)。
  • 妊娠区带蛋白在所有研究组中与可溶性fms样酪氨酸激酶-1/胎盘生长因子比值呈负相关,急性动脉粥样变与两蛋白无关。

核心结论

  • 参与动脉粥样硬化、高凝状态和蛋白错误折叠的蛋白在早发型子痫前期和胎盘功能障碍中失调,将二者联系起来并可能促成未来母体心血管疾病。

研究设计与样本

  • 检测549例妊娠孕妇血浆血清淀粉样蛋白A1与妊娠区带蛋白,分组为正常血压血糖正常对照258例、早发型子痫前期71例、晚发型子痫前期98例、妊娠期高血压30例、慢性高血压9例、糖尿病83例。
  • 547例有可溶性fms样酪氨酸激酶-1和胎盘生长因子血清水平,313例有急性动脉粥样变评估结果。
  • 采用Mann-Whitney U检验、卡方检验或Fisher精确检验比较组间临床特征与循环生物标志物,用Spearman rho评估相关性。

主要发现

  • 早发型子痫前期血清淀粉样蛋白A1较对照升高(17.1 vs 5.1 µg/mL,P<.001)。
  • 早发型子痫前期妊娠区带蛋白较对照降低(590 vs 892 µg/mL,P=.002)。
  • 糖尿病组妊娠区带蛋白较对照降低(683 vs 892 µg/mL,P=.01)。
  • 血清淀粉样蛋白A1与胎盘功能障碍(胎儿生长受限、可溶性fms样酪氨酸激酶-1/胎盘生长因子比值升高)相关。
  • 妊娠区带蛋白在所有研究组中与可溶性fms样酪氨酸激酶-1/胎盘生长因子比值呈负相关;急性动脉粥样变与血清淀粉样蛋白A1或妊娠区带蛋白无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension, and chronic hypertension), diabetes mellitus, and placental dysfunction confer an increased risk of long-term maternal cardiovascular disease. Preeclampsia is also associated with acute atherosis that involves lesions of uteroplacental spiral arteries, resembling early stages of atherosclerosis. Serum amyloid A1 is involved in hypercoagulability and atherosclerosis and may aggregate into amyloid-aggregations of misfolded proteins. Pregnancy zone protein may inhibit amyloid aggregation. Amyloid is involved in Alzheimer's disease and cardiovascular disease; it has been identified in preeclampsia, but its role in preeclampsia pathophysiology is unclear. OBJECTIVE: We hypothesized that serum amyloid A1 would be increased and pregnancy zone protein decreased in hypertensive disorders of pregnancy and diabetic pregnancies and that serum amyloid A1 and pregnancy zone protein would correlate with placental dysfunction markers (fetal growth restriction and dysregulated angiogenic biomarkers) and acute atherosis. STUDY DESIGN: Serum amyloid A1 is measurable in both the serum and plasma. In our study, plasma from 549 pregnancies (normotensive, euglycemic controls: 258; early-onset preeclampsia: 71; late-onset preeclampsia: 98; gestational hypertension: 30; chronic hypertension: 9; diabetes mellitus: 83) was assayed for serum amyloid A1 and pregnancy zone protein. The serum levels of angiogenic biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor were available for 547 pregnancies, and the results of acute atherosis evaluation were available for 313 pregnancies. The clinical characteristics and circulating biomarkers were compared between the pregnancy groups using the Mann-Whitney U, chi-squared, or Fisher exact test as appropriate. Spearman's rho was calculated for assessing correlations. RESULTS: In early-onset preeclampsia, serum amyloid A1 was increased compared with controls (17.1 vs 5.1 µg/mL, P<.001), whereas pregnancy zone protein was decreased (590 vs 892 µg/mL, P=.002). Pregnancy zone protein was also decreased in diabetes compared with controls (683 vs 892 µg/mL, P=.01). Serum amyloid A1 was associated with placental dysfunction (fetal growth restriction, elevated soluble fms-like tyrosine kinase-1 to placental growth factor ratio). Pregnancy zone protein correlated negatively with soluble fms-like tyrosine kinase-1 to placental growth factor ratio in all study groups. Acute atherosis was not associated with serum amyloid A1 or pregnancy zone protein. CONCLUSION: Proteins involved in atherosclerosis, hypercoagulability, and protein misfolding are dysregulated in early-onset preeclampsia and placental dysfunction, which links them and potentially contributes to future maternal cardiovascular disease.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Fosheim IK, Jacobsen DP, Sugulle M, et al. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction. Am J Obstet Gynecol MFM. 2022. PMID: 36334725. doi:10.1016/j.ajogmf.2022.100794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。